Document:

EX-10.14.2

 Exhibit 10.14.2 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

Confidential Materials omitted and filed separate with the Securities and Exchange Commission 

Triple asterisks denote omissions 

BINDING TERM SHEET FOR LICENSE 

dated February 22, 2017 

by and between 
 ATHENEX
PHARMACEUTICAL DIVISION, LLC (“Athenex”) 
 and 

GLAND PHARMA LIMITED (“Gland”) 

Definitions 
 Effective
Date: February 22, 2017 
 Product License: Gland is the manufacturer of the Products identified on Schedule A (Products). Gland
licenses Athenex to distribute the Product in North America (Territory). 
 Ownership: 

All right, title and interest in the ANDAs, the Product Information and any other results of the Development Activities related to the preparation of the ANDAs
for the Product shall be owned by Gland, subject to the terms of this License. 
 Development and Regulatory Fees: 

The Parties acknowledge and agree that as of the date hereof, Gland has completed the development of the Products, filed ANDA’s for the Products with FDA
and obtained regulatory approval while a few are awaiting regulatory approval from the FDA. To the extent that there are any additional fees associated with the development of the Products, including fees relating to manufacturing line change parts
required for the Products, or regulatory fees in connection with the ANDAs, Gland shall be responsible for all such fees. 
 Licensing Fee:

 The License granted by Gland to Athenex for the Products shall be on a non-exclusive basis. In
consideration of Gland granting such License to Athenex, Athenex shall pay Gland the License fees shown on Schedule A (II). The aggregate License fee for the Products identified is $3,150,000 (USD) and shall be payable in sixty (60) days from
invoicing as mentioned in Schedule A (II). 
 Term: 

The initial term of the License is 5 years from the launch of each product subject to automatic renewal for additional terms of 2 years, unless terminated by
either party providing notice 90 days in advance of a renewal date. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 Exclusivity: 

Gland will manufacture and supply the Products to Athenex for sale in the Territory on a non-exclusive basis,
and Gland will have right to manufacture and supply the Products to other Partners in the Territory. Athenex will market the Products on a private label basis under the “Athenex” brand in a commercially reasonably manner. Gland will be
identified on any Product labels as the ANDA holder of record. 
 Delivery of Product: 

Gland shall ship and deliver the Products Ex-Works Gland Pharma Warehouse, in accordance with Incoterms 2010. 

Net Profit Share: 
 During the Initial Term and any
renewal periods, Athenex shall pay to Gland a payment equivalent to percent (%) of the Net Profits from sale of the Products as defined in Schedule A. Athenex will provide payment to Gland on a quarterly basis not more than Thirty (30) days
following the end of each quarterly period following the Launch Date. Each payment shall be accompanied by a statement showing the Net Sales of the product for the applicable quarter, the aggregate Transfer Price paid for the units sold, and the
calculation of the Net Profit Share. “Net Profit” shall mean Net Sales less (i) the cost of the Product, including the Transfer Price, freight in, duty, customs, shipping, inventory, write offs and all other related costs of acquiring
the Product; and (ii) seven percent (7%) of Net Sales representing the overheads attributable to marketing and selling the Product and “Net Sales” shall mean, gross invoiced sales of a Product to all customers less
(i) chargebacks; (ii) freight and insurance charges; (iii) trade discounts, credits or allowances; (iv) costs of replacements, returns, recalls or rebates (v) wholesaler service charges; and (vi) sales, excise or value added
taxes paid on or in relation to the product; all as calculated in accordance with United States Generally Accepted Accounting Principles, or US GAAP. 

License Fee recoupment: Athenex will recoup 100% of the License Fee from the Net Profit prior to it sharing Profits with Gland for
Carboplatin, Gemcitabine, Cisplatin and Doxorubicin inj. 
 Legal Compliance: Gland represents and warrants it is in compliance with all
applicable laws and regulatory requirements for the Products, including the U.S. Drug Supply Chain and Security Act (DSCSA), and the Parties agree to maintain legal compliance with DSCSA during the term of the License. Gland further acknowledges and
agrees that the Products will be manufactured by Gland in accordance with the approved drug applications and U.S. Current Good Manufacturing Practices (CGMP). 

Regulatory Agent: Gland will be the sole Regulatory Agent for the Products in North America for the term of the License. Gland will be
responsible for all filings and interactions with the national regulatory agencies. As a marketing company, Athenex will be responsible for anything pertaining to submission of, Promotional materials; labelling filings with FDA and any Product
recalls. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 Definitive Agreement: This binding term sheet is intended to be legally binding, but will be
supplemented by definitive agreements which are mutually agreed by the parties. The definitive agreements will contain the terms of the License, customary representations and warranties, provision for payment terms, product warranties and product
liability, insurance, marketing issues, shipment, delivery and stocking, reporting, responsibility for regulatory filings, recalls and withdrawals, and other terms mutually agreed by the parties which are customary for definitive agreements covering
the subject matter contemplated by this License. As part of the definitive agreements, the Parties will enter into a Quality Agreement which will include appropriate policies and procedures to provide a reliable and consistent supply of Products to
the Territory. The parties will negotiate to enter into definitive agreements within 60 days after the date this letter is signed by both parties. 

Governing Law: This binding term sheet will be governed by the laws of the State of Illinois (without giving effect to choice of law or conflict
of law provisions). The parties agree to the exclusive jurisdiction and venue of the state and federal courts in the Northern District of the State of Illinois for the resolution of any disputes under this binding term sheet 

Confidentiality: The terms of this License are confidential and will not be disclosed without mutual agreement of the parties, except as
required in connection with the performance of this Agreement and the marketing of the Products or as required by applicable legal or regulatory requirements. 

Execution: This letter may be executed in counterparts, each of which shall be deemed to be an original and both of which together shall
constitute a single document. Facsimile or scanned signatures shall be relied on as if original signatures. 
 IN WITNESS WHEREOF, the authorized
representatives of the parties have executed this binding term sheet as of the Effective Date. 
  

									
	ATHENEX PHARMACEUTICAL DIVISION LLC	  		  	GLAND PHARMA LIMITED
					
	By:	 	  
	  		  	By:	 	  

	Name:	 	Jeff Yordon	  		  	Name:	 	Srinivas Sadu
	Title:	 	President	  		  	Title:	 	Chief Operating Officer

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

 Schedule A- Product Details 

 

	 	I.	Regulatory Status- 

  

	 	a.	Approved ANDAs: 

  

									
	 S.No
	  	 Product
	  	 Presentation
	  	Filing
date	 	Approval
date
	 1
	  	***	  	***	  	***	 	***
	 2
	  	***	  	***	  	***	 	***
	 3
	  	***	  	***	  	***	 	***

  

	 	b.	Filed ANDAs: 

  

									
	 S.No
	  	 Product
	  	 Presentation
	  	Filing
date	 	Approval
Estimate
	 1
	  	***	  	***	  	***	 	***
	 2
	  	***	  	***	  	***	 	***
	 3
	  	***	  	***	  	***	 	***

  

	 	II.	License Fee- 

  

	 	a.	Approved ANDAs: 

  

									
	 S.No
	  	 Product
	  	 Presentation
	  	License
Fee	 	BTS
Execution
(100%)
	 1
	  	***	  	***	  	***	 	***
	 2
	  	***	  	***	  	***	 	***
	 3
	  	***	  	***	  	***	 	***

  

	 	b.	Filed ANDAs: 

  

											
	 S.No
	  	 Product
	  	 Presentation
	  	License
Fee	 	BTS
Execution
(75%)	 	ANDA
approval
(25%)
	 1
	  	***	  	***	  	***	 	***	 	***
	 2
	  	***	  	***	  	***	 	***	 	***
	 3
	  	***	  	***	  	***	 	***	 	***

  

	 	III.	Commercials- 

  

	 	a.	Approved ANDAs: 

  

									
	 S.No
	  	 Product
	  	 Presentation
	  	Transfer
Price USD	 	Profit Share
(Athenex:
Gland)
	 1
	  	***	  	***	  	***	 	***
	 2
	  	***	  	***	  	***	 	***
	 3
	  	***	  	***	  	***	 	***

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 

	 	b.	Filed ANDAs: 

  

									
	 S.No
	  	 Product
	  	 Presentation
	  	Transfer
Price USD	 	Profit Share
(Athenex:
Gland)
	 1
	  	***	  	***	  	***	 	***
	 2
	  	***	  	***	  	***	 	***
	 3
	  	***	  	***	  	***	 	***

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.EX-10.15

 Exhibit 10.15 

FOIA CONFIDENTIAL TREATMENT REQUESTED 

Confidential Materials omitted and filed separate with the Securities and Exchange Commission 

Triple asterisks denote omissions 

JOINT VENTURE AGREEMENT 

THIS AGREEMENT (the “Agreement) is made as of the 22nd day of September, 2016, by and between SunGen Pharma LLC (“SunGen” DBA “Peterson
Pharmaceutical”), a New Jersey limited liability company, with its principal office and place of business at 303C College Road East, Princeton, NJ 08540 (“SunGen”), and Athenex Pharmaceutical Division which is a division of Athenex,
Inc., a Delaware corporation, with its principal office and place of business at Conventus Building, 1001 Main Street, Suite 600, Buffalo, NY 14203 (“Athenex”) (each a “Party”, and collectively, the “Parties”). 

WHEREAS SunGen is a specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products; 

WHEREAS Athenex is a global innovative pharmaceutical company focused on the development and commercialization of next generation therapies; 

WHEREAS the Parties wish to join together in a joint venture for the purpose of developing and commercializing certain human Rx, including 503(b) compounding,
pharmaceutical products; 
 NOW THEREFORE BE IT RESOLVED, in consideration of the mutual covenants, promises, warranties and other good and valuable
consideration set forth herein, the Parties agree as follows: 
 1. Formation. The joint venture formed pursuant to this Agreement (the “Joint
Venture”) shall do business under the name Peterson Athenex Pharmaceuticals, LLC, which the parties expect shall be formed as a Delaware limited liability company by Oct 15, 2016, and shall have its legal address at 303C College Road East,
Princeton, NJ 08540. Athenex will generate the initial drafts of the limited liability company formation documents for the Joint Venture (the “Joint Venture Documents”) for review by Sungen by no later than September 30th. The parties
agree to review and negotiate the definitive terms of such documents in good faith and in a timely fashion following delivery of the draft documents to Sungen; provided, however, that the parties will not be bound to the terms of such documents
until they are mutually approved. SunGen will own 51% and Athenex will own 49% shares of stock of the Joint Venture. A bank account in the name of the Joint Venture shall be established, into which the financial contributions of the Parties shall be
deposited, for use in the set-up, operation, and administration of the Joint Venture. The Joint Venture shall be considered in all respects a joint venture between the Parties, and nothing in this Agreement shall be construed to create a partnership
or any other fiduciary relationship between the Parties. 
 2. Purpose. The Joint Venture shall be formed for the purpose of development, marketing and
commercialization of pharmaceutical products, initially, Terbutaline Sulfate Injectable and Lincomycin HC1 Injectable. No limit is set on the number of products that might be added to the JV in the future. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

1 

 3. Contributions. 

3.1 The sales and marketing of two drug products, namely Terbutaline Sulfate Injectable and Lincomycin HC1 injectable, shall be placed
initially into the JV. The Parties shall each make an initial contribution to the Joint Venture according to the following terms, upon the reaching of mutual agreement between the parties with respect to the final form of the Joint Venture
Documents: 
  

	 	a.	SunGen’s Contribution: Five year exclusive human Rx sales right in the US, Canada and Mexico for FDA approved abbreviated new drug application (ANDA) of Terbutaline Sulfate drug product; manufacture of commercial
batches of the Terbutaline Sulfate drug product; Exclusive human Rx sales right in the US for Lincomycin injectable products ANDA owned by SunGen; development of ANDA of Lincomycin injectable drug products, 2 mL Vials — NDC 0009-0555-01 and 10
mL Vials — NDC 0009-0555-02, and submission of the ANDA for FDA approval, and manufacture of commercial batches of the Lincomycin drug products upon approval of the ANDA by FDA; and Licomycin API, formulation and processes to be used for the
sole purpose for the joint 503(b) compounding business with Athenex. 

  

	 	b.	Athenex’s Contribution: Manufacturing costs of the Terbutaline Sulfate drug product; Athenex’s portion of the development and manufacture and associated costs of Lincomycin injectable drug products, which is
$375,000, of which the initial $*** shall be paid by Athenex to SunGen upon signing of the reaching of mutual agreement between the parties with respect to the final form of the Joint Venture Agreements; milestone payments according to Exhibit B;
marketing and sales of the Terbutaline drug product and Lincomycin injectable drug products, including 503(b) products, into the U.S. human health market; Lincomycin 503(b) products manufactured by Athenex (manufacture of the 503(b) products shall
stop when Lincomycin ANDA is approved by FDA, and Athenex shall return all know-how, formula, process, analytical methods, trade-secrets and other related Intellectual Property to SunGen); sales and marketing expenses (5-10% treated as sales expense
of JV). 

 3.2 The sales and marketing of ANDA products of SunGen or SunGen partners will be evaluated by Athenex and agreed to
by both Parties on the valuation/milestone payments/profit sharing, and the exclusive human Rx sales rights will be placed into JV, if agreement is reached. Athenex and its affiliates shall not, directly or indirectly, compete with SUNGEN by
engaging in the development or assist the development of, manufacture, market, promote, use, license, distribute, sell, have sold, import, export, make or have made any drug or other product which is a generic version of the Terbutaline or
Lincomycin, without SUNGEN’s prior written consent. Athenex shall make purchase orders from SunGen of the drug products once they are entered into the JV and have been approved by the FDA. All drug products to be sold by the JV shall be labeled
“Peterson Athenex” in conjunction with the “Peterson Logo”. The JV shall have the exclusive rights to sell the products into the US human Rx business, while SunGen and its partners shall hold the ANDA ownership. 

 

	 	a.	Upon the reaching of mutual agreement between the parties with respect to the final form of the Joint Venture Documents, Athenex shall place the first purchase order of at least one (1) full batch of Terbutaline drug
product from SunGen according to Exhibit A. 

  

	 	b.	Upon approval of ANDA for Lincomycin Injectable drug product by the FDA, Athenex shall place purchase orders for the drug product from SunGen within 3 months after the ANDA approval. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

2 

 4. Distribution of Profits. The Joint Venture Documents shall specify that any and all net profits accruing to
the Joint Venture shall be held and distributed to the Parties in equal shares, i.e., split equally (50/50) between SunGen and Athenex, except for the sale of Terbutaline Injectable, where the profit shall be split 75/25 between SunGen and Athenex,
respectively. For profit calculation purpose, 5-10% of sales and marketing costs actually spent by Athenex on the sale of products shall be taken into account as the costs of JV in the Joint Venture Documents. 

5. Management. The Joint Venture Documents shall specify that the JV LLC shall be managed by a Board of Directors comprised of four (4) Directors, two of whom
shall be appointed by SunGen, including the Chairperson of the Board, and the other two by Athenex, and shall specify the following additional terms, in addition to other terms and provisions to be set forth therein. 

5.1 The Board shall appoint Mr. Jeff Yordon as the initial Chief Executive Officer in charge of daily operations of the JV. 

5.2 Board meetings shall be held quarterly either in person or by teleconference after results of sales for that quarter become available. 

5.3 Decisions on the following matters will need approval by the Board with 60% of voting rights: 

 

	 	a.	Sale of Assets or Stock of JV 

  

	 	b.	Sale or dissolution of the JV 

  

	 	c.	Profit distributions, including changes in splitting 

  

	 	d.	Hiring of JV Employees 

  

	 	e.	Tax treatment of distributions or profits 

  

	 	f.	Hiring of accountants, lawyers or consultants 

  

	 	g.	Spending on JV items 

  

	 	h.	Sales or Marketing plans or strategies 

  

	 	i.	Placement of additional products either acquired or developed into the JV 

  

	 	j.	Other items mutually negotiated and agreed upon. 

 6. No Exclusivity. Neither Party shall be obligated to offer
any business opportunities or to conduct business exclusively with the other Party by virtue of this Agreement. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

3 

 7. Term. This Agreement shall remain in full force and effect for a period of ninety nine (99) years from the
date of this Agreement (the “Initial Term”) or until and unless both parties agree to dissolve in writing. At any time, this Agreement may be terminated by mutual written consent of the Parties, as provided in Section 9, or in the event of
a parties breach of the terms of this Agreement or the Joint Venture Documents which is not cured within 20 business days following delivery of written notice. If this Agreement either expires or is terminated, the parties agree that the Joint
Venture entity shall be terminated, dissolved and liquidated as well, and all Parties’ obligations under this Agreement with respect to the operation and administration of the Joint Venture shall no longer have force or effect. 

8. Confidentiality. Any information pertaining to either Party’s business to which the other Party is exposed as a result of the relationship
contemplated by this Agreement shall be considered to be “Confidential Information.” Neither Party may disclose any Confidential Information to any person or entity, except as required by law, without the express written consent of the
affected Party. 
 9. Further Actions. As provided herein, the Parties hereby agree to execute any further documents and to take any necessary actions to
complete the formation of the Joint Venture; provided, however, that if the parties are unable to mutually agree upon to the terms of the definitive Joint Venture Documents by October 15th, then either party shall have the right to terminate this
Agreement. 
 10. Assignment. Neither Party may assign or transfer their respective rights or obligations under this Agreement without prior written consent
from the other Party. Except that if the assignment or transfer is pursuant to a sale of all or substantially all of a Party’s assets, a merger, a sale of a controlling interest of its stock, or otherwise pursuant to a sale of a Party’s
business, then no consent shall be required. 
 11. Governing Law. This Agreement shall be construed in accordance with, and governed in all respects by,
the laws of the State of New Jersey without regard to conflicts of law principles. 
 12. Counterparts. This Agreement may be executed in several
counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one agreement. Facsimile or scanned signatures shall be treated as equivalent to the original signatures. 

13. Severability. If any part or parts of this Agreement shall be held unenforceable for any reason, the remainder of this Agreement shall continue in full
force and effect. If any provision of this Agreement is deemed invalid or unenforceable by any court of competent jurisdiction, and if limiting such provision would make the provision valid, then such provision shall be deemed to be construed as so
limited. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

4 

 14. Notice. Any notice required or otherwise given pursuant to this Agreement shall be in writing and mailed
certified return receipt requested, postage prepaid, or delivered by overnight delivery service, addressed as follows: 
  

			
	If to SunGen:	  	Dr. Isaac Liu, Co-CEO and President
		  	303C College Road East
		  	Princeton, NJ 08540
		
	If to Athenex:	  	Mr. James Hussey
		  	Executive Vice President
		  	10 Martingale Road
		  	Suite 203
		  	Schaumburg, Illinois 60017
		
	If to Joint Venture	  	Dr. Isaac Liu
		  	303C College Road East
		  	Princeton, NJ 08540

 15. Headings. The headings for section herein are for convenience only and shall not affect the meaning of the
provisions of this Agreement. 
 16. Entire Agreement. This Agreement, and after mutually agreed upon by the parties, the Joint Venture Agreements,
constitutes the entire agreement between SunGen and Athenex, and supersedes any prior understanding or representation of any kind preceding the date of this Agreement. There are no other promises, conditions, understandings or other agreements,
whether oral or written, relating to the subject matter of this Agreement. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed the
day and year first above written. 
  

					
	SunGen PharmaLLC	 		 	Athesnex Pharmaceutical Division
			
	  
 Signature
	 		 	  
 Signature

			
	 Isaac Liu
	 		 	  

	Print Name	 		 	Print Name
			
	 Co-CEO and President
	 		 	  

	Title	 		 	Title

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

5 

 EXHIBIT A 

Transfer Price 
  

									
	 Active Ingredient
	  	 Dosage Form;
Route
	  	 Strength
	  	 Pack Size
	  	 Transfer Price/Market Share

	 Terbutaline Sulfate
	  	Injectable;
Injection	  	1MG/ML	  	10	  	 1. ***/vial — at Launch

2. ***/vial — market share greater than/equal to 25% but less than 40%

3. ***/vial — market share greater than or equal to 40%

 Batch Size: 42,500 vials 

Profit Split SunGen and Athenex: 75%: 25% 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

6 

 EXHIBIT B 

Development Costs. As compensation for the development work on Lincomycin Injectable, Athenex shall pay SunGen the sum of $375,000 in milestones as
follows: 
  

	 	1.	USD $*** payment shall be made upon signing of the Agreement. 

  

	 	2.	USD $*** non-refundable payment shall be made upon acceptance of the formulation development. SunGen and its partner(s) then execute media-fill batches and e-batches productions. Batch records and certificates of
conformance of E-batches will be provided once finished. Stability testing of the Product of E-batches will then be executed. 

  

	 	3.	USD $*** non-refundable payment shall be made after successful 6-month accelerated stability testing. 

  

	 	4.	USD $*** payment shall be made upon acceptance of prepared CTD module II and III for ANDA submission of the Product. 

  

	 	5.	USD $*** payment shall be made when FDA grants the ANDA approval of the Product. 

 These Development Costs do
not include cost for Reference Listed Drug (RLD). Lincomycin API and materials for developments of formulation and analytical methods and batch productions are included in the cost. 

 

	3.2	Price of Commercial Product. 

  

			
	 Product
	  	Price Per single vial units
		
	 2 mL vial
	  	USD ***/vial
		
	 10 mL vial
	  	USD ***/vial

 2 mL Vials — NDC 0009-0555-01 

10 mL Vials — NDC 0009-0555-02 

8% annual GDUFA (facility) fee shall be paid by SunGen and Athenex equally from the year when the approval of the US ANDA occurs. 

  
 *** = Portions of this exhibit have
been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. 
  

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]